[Skip to Content]
[Skip to Content Landing]
February 1960

Further Experimental Evaluation of Two New CorticosteroidsTriamcinolone (Aristocort) and Dexamethasone (Deronil) Preparations in the Therapy of Ocular Inflammation

Author Affiliations

Washington, D.C.
From the Eye Research Section, Department of Surgery, Georgetown University Medical Center.; Present address of Dr. Chavan: c/o Shri. N.B. Suryawanshi, Buldana, Bombay State, India.; Research Fellow in Ophthalmology (Dr. Chavan), Professor of Ophthalmology (Dr. Cummings), and Clinical Associate Professor of Ophthalmology (Dr. Egan), Georgetown University Medical Center.

AMA Arch Ophthalmol. 1960;63(2):319-329. doi:10.1001/archopht.1960.00950020321016

Scientific research and clinical analysis of the newer adrenal corticosteroids are continuously being carried on to evaluate their ability to suppress inflammation, edema, and allergic reaction, with a minimum of side reactions. These research efforts have resulted in improved topical and systemic cortical steroids that provide higher therapeutic effect with low dosage and a minimum amount of side-effects.

The analogues, triamcinolone, prednisone, and prednisolone, were found to be superior to cortisone and hydrocortisone.1-5 Experimental studies on uveitis revealed that a given anti-inflammatory response required doses several times greater of cortisone and hydrocortisone than triamcinolone-free alcohol, prednisone, or prednisolone.1,4,5

The most recent forms of adrenal steroids are triamcinolone (Aristocort) and dexamethasone (Deronil), which have been considered to be the more potent and relatively least toxic of the corticosteroids. Triamcinolone-free alcohol and triamcinolone diacetate are the parent compounds. The three special derivatives of triamcinolone-free alcohol are triamcinolone acetonide, triamcinolone acetonide

First Page Preview View Large
First page PDF preview
First page PDF preview